9.7
Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated…
β1 receptors in the heart and kidneys regulate cardiac output and renin release.
Under stress conditions, the activation of these receptors by catecholamines increases blood pressure and promotes optimal organ function.
β2 receptors in lungs and blood vessels induce smooth muscle relaxation, promoting bronchodilation and vasodilation, enhancing oxygen delivery and easing respiration.
β-blockers competitively block these receptors; nonselective ones target both β1 and β2-receptors, while selective ones bind to β1 receptors.
In hypertensive patients, nonselective β-blockers, like propranolol, inhibit β1 receptor activity, reducing cardiac output and renin release, lowering blood volume and pressure.
Propranolol's nonselective nature also blocks β2 receptors, worsening bronchoconstriction in hypertensive patients with respiratory disorders.
In such cases, cardioselective β-blockers, such as metoprolol and atenolol, are preferred. They specifically target β1 receptors of the heart, effectively reducing blood pressure without inducing airway constriction.
Atenolol's limited blood-brain barrier entry minimizes CNS side effects, contrasting propranolol's active penetration, leading to potential CNS-related side effects.
View the full transcript and gain access to JoVE Core videos
Q1: How do β1 and β2 receptors differ in location and function?
β1 receptors are located in the heart and kidneys, where they increase heart rate, contractility, and renin release to enhance blood pressure during stress. β2 receptors are found in lungs, blood vessels, and skeletal muscles, triggering smooth muscle relaxation that causes bronchodilation and vasodilation, improving oxygen delivery and easing respiration.
Q2: What is the difference between nonselective and selective β-blockers?
Nonselective β-blockers like propranolol block both β1 and β2 receptors, reducing blood pressure but potentially worsening bronchoconstriction in patients with respiratory disorders. Selective β-blockers such as metoprolol and atenolol target only β1 receptors, effectively lowering blood pressure while avoiding airway constriction and reducing unwanted respiratory side effects.
Q3: Why are cardioselective β-blockers preferred for hypertensive patients with asthma?
Cardioselective β-blockers like metoprolol and atenolol specifically target β1 receptors in the heart, reducing blood pressure without inhibiting β2-mediated bronchodilation. This selectivity prevents increased airway resistance and bronchoconstriction, making them safer for patients with respiratory conditions like asthma or COPD who require blood pressure management.
Q4: How does propranolol lower blood pressure in hypertensive patients?
Propranolol inhibits β1 receptor activity in the heart and kidneys, reducing cardiac output and renin release. This decreases blood volume and peripheral resistance, effectively lowering blood pressure. However, its nonselective nature also blocks β2 receptors, which can exacerbate respiratory conditions in susceptible patients.
Q5: What are the central nervous system effects of different β-blockers?
Propranolol has high lipophilicity, allowing it to cross the blood-brain barrier and cause CNS-related side effects such as fatigue or depression. Atenolol, a selective β-blocker with low lipophilicity, has limited blood-brain barrier entry, minimizing CNS side effects. This makes atenolol a better choice for patients sensitive to neurological complications.
Q6: How do β-blockers competitively inhibit catecholamine effects?
β-blockers competitively block β-receptor sites by binding where norepinephrine and epinephrine normally attach. Under stress, catecholamines typically activate these receptors to increase blood pressure and heart function. By occupying these sites, β-blockers prevent catecholamine activation, reducing cardiac output and renin release to lower blood pressure.
Q7: Why does blocking β2 receptors cause problems in respiratory disease patients?
β2 receptors in lungs normally promote smooth muscle relaxation and bronchodilation when activated. Nonselective β-blockers like propranolol inhibit this β2-mediated bronchodilation, increasing airway resistance and worsening bronchoconstriction. This is particularly dangerous for patients with asthma or COPD, making selective β-blockers the safer therapeutic option.